



PRESS RELEASE
07 November 2024 08:30:00 CET

Strategic partnership for Stockholm3 in Switzerland

A3P Biomedical, a leading innovator in prostate cancer diagnostics, has entered a strategic partnership with labor team, a top-tier Swiss laboratory based in Goldach. Effective November 1, 2024, this collaboration will make Stockholm3, a pioneering blood-based diagnostic for early detection of aggressive prostate cancer, available to men throughout Switzerland.

labor team will handle all logistics and wet lab analysis for Stockholm3 in Switzerland, granting Swiss healthcare providers and patients access to Stockholm3 for early detection of prostate cancer. Known for setting new standards in laboratory medicine and offering customized analyses for individual requirements, labor team will leverage their marketing team, sales force, and logistics to deliver Stockholm3 nationwide, ensuring that men across Switzerland can benefit from this innovative testing solution.

“With our mission of making Stockholm3 the standard of care in prostate cancer diagnostics, we are thrilled to partner with labor team. Their commitment to innovation, transparency and individual diagnostics aligns seamlessly with our goal to transform prostate cancer detection,” says Martin Steinberg, Executive Chairman of A3P Biomedical.

“This partnership enables us to address an urgent medical need, providing Swiss men with an accurate and reliable diagnostic test to improve prostate cancer outcomes,” says Alain Cahen, CEO of labor team.

As prostate cancer remains the most common cancer among men, early detection and appropriate risk stratification are critical to optimizing treatment and improving survival rates. Stockholm3 combines genetic, protein, and clinical markers, enabling a far more precise assessment of prostate cancer risk than standard PSA tests. Studies show that Stockholm3 detects 41-89% more cases of aggressive cancer while reducing unnecessary biopsies by 37-52%.

With this partnership, A3P Biomedical and labor team are advancing their shared vision to improve diagnostic options and healthcare outcomes for men in Switzerland.

For more information about the Stockholm3 test, please visit www.stockholm3.com

For more information on how to access Stockholm3 in Switzerland, please contact labor team at +41 71 844 45 45.

A3P Biomedical AB (publ)



For additional information, please contact:

Cecilia Edström, acting CFO
Telephone: +46 72 226 23 28
Email: cecilia.edstrom@a3p.com

About A3P Biomedical

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P's main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com

About Stockholm3

Stockholm3 is a blood-based prostate cancer test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml. Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 41-89% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 37-52% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about Stockholm3 and our clinical studies please visit www.stockholm3.com/

About prostate cancer

Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.

A3P Biomedical AB (publ)



Attachments

[Strategic partnership for Stockholm3 in Switzerland](#)